BioSpace News Archive

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced that its liquid biopsy focused subsidiary Inivata Limited has entered into a clinical collaboration with the Princess Margaret Cancer Center in Toronto, Canada, for the use of Inivata’s liquid biopsy assays, InVisionFirst®-Lung and RaDaR™ in two separate studies.

Versantis AG, a clinical-stage company developing novel therapies for rare liver diseases and rare pediatric diseases, announced the appointment of Prof Dr Katharina Staufer as Chief Medical Officer.

Pharnext SA is pleased to announce the strengthening of its senior management team with the appointments of Raj Thota, as Chief Manufacturing Officer and Head of CMC, Abhijit Pangu as the Head of Regulatory Affairs and the promotion of Xavier Paoli to Chief Operating Officer.

Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that the first clinical trial sites in the Asia-Pacific region are now open for patient enrollment into the OPT-302 Phase 3 pivotal clinical program for the treatment of wet age-related macular degeneration.

Sage Therapeutics, Inc. and Biogen Inc. announced their plan to submit a New Drug Application to the U.S. Food and Drug Administration for zuranolone, an investigational two-week, once-daily therapeutic in the second half of 2022.

Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces that Boehringer Ingelheim has exercised its option to license Oxford Biomedica’s lentiviral vector technology to manufacture, register and commercialise BI 3720931, a lentiviral vector-based gene therapy for the treatment of cystic fibrosis (CF).

Galera Therapeutics, Inc. (Nasdaq: GRTX), today announced results from the Phase 3 ROMAN trial of avasopasem manganese (avasopasem) for severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC) undergoing standard-of-care radiotherapy.

ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), today announced that a poster presentation will be made at the virtual 2021 International Society for Influenza and other Respiratory Virus Diseases - World Health Organization (ISIRV-WHO) Conference, which will take place on October 19-22.

Seqirus today announced new real-world evidence (RWE) supporting the effectiveness of its cell-based and adjuvanted seasonal influenza vaccines.

LLR Partners today announced an investment in Genesee Scientific , a manufacturer and distributor of products to global life science markets.